RESEARCH presented at ACR Convergence 2025 highlights a potential new role for GLP-1 receptor agonists, medications widely used for type 2 diabetes and obesity, in the treatment of rheumatoid arthritis (RA).
RESEARCH presented at ACR Convergence 2025 highlights a potential new role for GLP-1 receptor agonists, medications widely used for type 2 diabetes and obesity, in the treatment of rheumatoid arthritis (RA).